Complete final
Ch1: Orientation to Pharmacology
Properties of an Ideal Drug
Effectiveness: The drug must effectively produce the desired therapeutic effect.
Safety: The drug should cause no harmful effects when used correctly.
Selectivity: The drug should target specific sites and not produce side effects.
Reversible Action: Effects of the drug should be reversible.
Predictability: The effects of the drug should be predictable; knowing the drug's behavior helps in patient care.
Ease of Administration: The administration should be simple and practical.
Freedom from Drug Interactions: The drug should not interact adversely with other drugs or substances.
Low Cost: The drug should be affordable for patients and healthcare systems.
Chemical Stability: The drug should remain stable under a variety of conditions.
Possession of a Simple Generic Name: A simple name ensures easy communication among healthcare providers.
Therapeutic Objective/Goal
Factors that determine the intensity of drug responses include:
Administration: How the drug is given can affect its effect.
Pharmacokinetics: The study of how drugs move through the body—absorption, distribution, metabolism, and excretion.
Pharmacodynamics: The study of the effects of drugs on the body.
Sources of Individual Variation: Genetic factors, health conditions, and environmental influences can affect drug response.
Ch2: Application of Pharmacology in Nursing Practice
Drug Cards:
Acetaminophen: Commonly used for pain relief and fever reduction.
Ibuprofen: Non-steroidal anti-inflammatory drug (NSAID) used for pain relief, inflammation, and fever.
Application of Pharmacology in Patient Care
Pre-administration Assessment:
Collect baseline data.
Identify high-risk patients.
Dosage and Administration:
Different indications may require different dosages.
Dosages may differ depending on the route of administration.
Guidelines for ensuring correct administration include verifying patient identity and medication label, and dosage calculations.
Caution: Do not administer any drug without understanding its purpose.
Promoting Therapeutic Effects:
Minimize adverse effects.
Minimize adverse interactions.
Make PRN (as needed) decisions.
Evaluate responses to medications.
Manage toxicity.
Patient Education in Pharmacology:
Discuss drug names, dosages, schedules, and adherence.
Techniques for administration and storage.
Importance of duration of drug use.
Strategies to promote therapeutic effects and reduce side effects.
Application of the Nursing Process in Drug Therapy:
Carry out the nursing process in drug therapy, with emphasis on pre-administration assessment, baseline data for evaluating therapeutic and adverse effects, and high-risk patient identification.
Assess the patient’s capacity for self-care.
Ch 3: application of pharmacology in nursing practice
The process of developing new drugs involves several critical steps to ensure safety and efficacy.
The Randomized Controlled Trial
Use of Controls: Controls are used to provide a baseline for comparison against the drug being tested.
Randomization: Participants are randomly assigned to different groups to eliminate bias.
Blinding: Single or double blinding is used to prevent bias in treatment administration and reporting of results.
Stages of New Drug Development
Pre-clinical Testing:
Done in laboratories and on animals to assess safety and biological activity.
Clinical Testing:
Phase I: Focus on safety and dosage; involves a small number of healthy volunteers.
Phase II: Tests the effectiveness of the drug; involves a larger group of patients who have the disease.
Phase III: Compares the new drug to standard treatments; involves thousands of participants.
Phase IV: Post-marketing Surveillance: Conducted after the drug is approved to monitor its long-term effects and performance in the general population.
Limitations of the Testing Procedure
Limited Information on Women and Children: Clinical trials often under-represent these groups, affecting the applicability of results.
Failure to Detect All Adverse Effects: Some side effects may not surface until after the drug is widely used.
Exercising Discretion Regarding New Drugs: Healthcare providers must carefully evaluate the risks versus benefits of newly released medications.
Drug Names
Three Types of Drug Names:
Chemical Name: Describes the chemical structure.
Generic Name: Official medical name; universally recognized.
Brand Name: Trademarked name by the manufacturer; may vary by region.
Which Name to Use, Generic or Brand?
Problems with Brand Names: Can lead to confusion due to similar-sounding names or multiple brand names for the same drug.
Generic Products Versus Brand-Name Products
Typically, generic products are less expensive than brand-name but contain the same active ingredients, strength, and dosage forms.
Over-the-Counter (OTC) Drugs: These are available without a prescription and can provide relief for various health conditions.
Sources of Drug Information
Newsletters: These can provide periodic updates on drug news and studies.
Reference Books: Comprehensive details on drugs and pharmacological data.
The Internet: A readily accessible but variable source of drug information requiring critical evaluation of reliability.
Ch 4: Pharmacokinetics
Warfarin: An anticoagulant used to prevent thrombosis and embolism.
Nitroglycerin: A vasodilator used for angina and heart failure.
Application of Pharmacokinetics in Therapeutics
Passage of Drugs Across Membranes
Membrane Structure Three Ways to Cross a Cell Membrane:
Passive diffusion
Facilitated diffusion
Active transport
Absorption
Factors Affecting Drug Absorption
Drug formulation
Route of administration
Gastric pH and food intake
Characteristics of Commonly Used Routes of Administration:
Intravenous:
Barriers to Absorption: None
Absorption Pattern: Immediate
Advantages: Rapid onset, control over drug levels.
Disadvantages: Requires skilled personnel, risk of infection.
Intramuscular:
Barriers to Absorption: Muscle tissue
Absorption Pattern: Variable depending on blood flow.
Advantages: Faster than oral, depot injections.
Disadvantages: Pain and discomfort, variability in absorption.
Subcutaneous:
Barriers to Absorption: Fat tissue
Absorption Pattern: Slower than IM.
Advantages: Easier to administer.
Disadvantages: Limited to small volumes.
Oral:
Barriers to Absorption: Gastric acid, food interactions.
Absorption Pattern: Influenced by GI motility.
Drug Movement after Absorption: Through portal circulation to the liver.
Advantages: Convenient, safe, and economical.
Disadvantages: Slower onset, first-pass metabolism.
Comparing Oral Administration with Parenteral Administration: Parenteral administration often provides quicker absorption and direct entry into circulation compared to oral routes.
Pharmaceutical Preparations for Oral Administration:
Tablets: Solid form
Enteric-Coated Preparations: Protects drug from stomach acid
Sustained-Release Preparations: Gradual release over time
Blood Flow to Tissues: Affects distribution; increased blood flow enhances pharmacokinetics.
Additional Routes of Administration: Includes transdermal, inhalation, and topical.
Distribution Exiting the Vascular System Typical Capillary Beds: Determine drug distribution into tissues. The Blood-Brain Barrier: Limits drug penetration into the CNS. Placental Drug Transfer: Risk for fetal exposure. Protein Binding: Influences drug availability in circulation.
Entering Cells: Mechanisms of how drugs enter cells vary.
Metabolism Hepatic Drug-Metabolizing Enzymes: Alter drug structure for elimination. Therapeutic Consequences of Drug Metabolism:
Accelerated Renal Drug Excretion
Drug Inactivation
Increased Therapeutic Action
Activation of Prodrugs
Increased or Decreased Toxicity Special Considerations in Drug Metabolism:
Age
Induction and Inhibition of Drug-Metabolizing Enzymes
First-Pass Effect
Nutritional Status
Competition Between Drugs
Enterohepatic Recirculation
Excretion Renal Drug Excretion: Steps in Renal Drug Excretion:
Glomerular Filtration: Moves drugs to urine.
Passive Tubular Reabsorption: Drugs can be reabsorbed into the bloodstream.
Active Tubular Secretion: Active transport of drugs into urine.
Factors that Modify Renal Drug Excretion:
pH-Dependent Ionization
Competition for Active Tubular Transport
Age
Non-renal Routes of Drug Excretion: Includes breast milk and sweat.
Time Course of Drug Responses
Plasma Drug Levels: Critical for therapeutic effectiveness. Clinical Significance of Plasma Drug Levels:
Minimum Effective Concentration (MEC)
Toxic Concentration
Therapeutic Range: Determines effectiveness without toxicity. Single-Dose Time Course: Evaluates the effect over time. Drug Half-Life: Influences dosing schedules. Drug Levels Produced with Repeated Doses: Accumulation over time.
How Plateau Drug Levels are Achieved: Steady-state concentration through consistent dosing.
Time to Plateau: Typically takes 4-5 half-lives of the drug. Ways to Reduce Fluctuations in Drug Levels: Use of sustained-release formulations. Loading Doses Versus Maintenance Doses: Loading doses achieve therapeutic levels quickly, while maintenance doses are used to sustain levels.
Decline from Plateau: Plasma drug levels decline after discontinuation.
Ch 5: Pharmacodynamics
Pharmacodynamics: The study of biochemical and physiological effects of drugs on the body and the molecular mechanisms by which those effects are produced.
Dose-Response Relationships
Meaning of the basic components of the dose-response curve:
Phase 1: Characterized by low doses where a slight increase in dose results in a small increase in response.
Phase 2: Exponential growth phase where a given increase in dose leads to a comparatively larger increase in response.
Phase 3: Plateau phase where further increases in dose result in little to no increase in response, indicating maximal effect or efficacy.
Maximal Efficacy: The greatest effect a drug can produce, determined by the drug's mechanism of action and context of administration.
Relative Potency: A measure of how much drug is needed to elicit a given effect; more potent drugs require lower doses to achieve the same effect compared to less potent drugs.
Drug-Receptor Interactions
General Interaction:
The interaction between a drug (D) and receptor (R) can be represented as:
Important properties of receptors and drug-receptor interactions:
The Four Primary Receptor Families:
Cell-Membrane-Embedded Enzymes: Receptors with intrinsic enzymatic activity upon binding.
Ligand-Gated Ion Channels: Receptors that form an ion-conducting pore upon binding with a ligand, allowing ions to pass through the membrane.
G Protein-Coupled Receptor System: Receptors that activate intracellular signaling pathways through G proteins.
Transcription Factor Receptors: Receptors that, after binding with a ligand, translocate to the nucleus and regulate gene expression.
Selectivity of Drug Action: The ability of a drug to preferentially trigger certain biological responses at specific targets while minimizing effects on non-target systems.
Theories of Drug-Receptor Interaction
Simple Occupancy Theory: The response of a tissue to a drug is proportional to the number of receptors occupied by the drug.
Modified Occupancy Theory: Accounts for both affinity (how well a drug binds to its receptor) and intrinsic activity (the ability of the drug-receptor complex to produce a response).
Affinity: Refers to the strength of the interaction between the drug and its receptor.
Intrinsic Activity: Refers to the ability of a drug to activate a receptor once bound, producing a biological effect.
Agonists, Antagonists, and Partial Agonists
Agonists: Drugs that bind to receptors and activate them, leading to a biological response.
Antagonists: Drugs that bind to receptors but do not activate them; they block the action of agonists.
Noncompetitive versus Competitive Antagonists:
Competitive Antagonists: Compete with agonists for binding to the active site of receptors.
Noncompetitive Antagonists: Bind to an alternative site on the receptor; their effect cannot be overcome by increasing the concentration of agonists.
Partial Agonists: Drugs that bind to receptors and activate them but with less efficacy than full agonists; they can also act as antagonists in the presence of full agonists.
Regulation of Receptor Sensitivity
Refers to the mechanisms that adjust receptor activity in response to changes in drug concentration, often resulting in transient desensitization or upregulation of receptors.
Drug Responses that do not Involve Receptors
Some drug actions may occur via mechanisms that do not involve receptor binding, such as physical or chemical interactions.
Interpatient Variability in Drug Responses
Measurement of Interpatient Variability: Variability in the response of patients to drugs, influenced by factors such as genetics, environment, and comorbid conditions.
The ED50 (Effective Dose 50): The dose at which 50% of the population experiences the desired therapeutic effect; used to assess variability in drug response.
Clinical Implications of Interpatient Variability: Important to recognize in clinical practice to optimize dosing strategies and minimize adverse effects
Ch 6: DRUG INTERACTIONS
Definition: Drug-drug interactions occur when one drug affects the pharmacological effect of another drug.
A. Consequences of Drug-Drug Interactions
i. Intensifications of Effects
1. Increased therapeutic effects: Enhanced intended effects of the drugs.
2. Increased adverse effects: Amplified unwanted side effects from drug combination.
ii. Reduction of Effects
1. Reduced therapeutic effects: Diminished desired effects due to interaction.
2. Reduced adverse effects: Decreased side effects from interaction.
iii. Creation of a Unique Response: This can lead to unexpected effects not seen with individual drugs.
B. Basic Mechanisms of Drug-Drug Interactions
i. Direct Chemical or Physical Interactions: Occurs when drugs interact outside the body, e.g., precipitate formation.
ii. Pharmacokinetic Interactions: Alters how the body handles the drugs.
1. Altered absorption: Changes in how the drug is absorbed into the body.
2. Altered distribution:
a. Competition for protein binding: Drugs may compete for binding sites on proteins, affecting their availability.
b. Alteration of extracellular pH: Changes in pH can influence drug solubility and absorption.
c. Altered metabolism:
d. Induction of CYP Isoenzymes: Some drugs can increase the activity of cytochrome P450 enzymes, leading to faster metabolism of other drugs.
e. Inhibition of CYP Isoenzymes: Conversely, some drugs can inhibit these enzymes, leading to slower metabolism.
3. Altered renal excretion: Changes in how drugs are filtered and excreted by the kidneys.
4. Interactions that involve P-Glycoprotein: This transporter can affect drug absorption and distribution.
iii. Pharmacodynamic Interactions:
1. Interactions at the same receptor: Drugs may enhance or inhibit effects by competing at the same receptor site.
2. Interactions resulting from actions at separate sites: Drugs may have complementary effects through different mechanisms.
C. Clinical Significance of Drug-Drug Interactions
Understanding these interactions is critical for patient safety and effective medication management.
D. Minimizing Adverse Drug-Drug Interactions
Strategies include careful medication management, reviewing patient histories, and using therapeutic drug monitoring.
II. DRUG-FOOD INTERACTIONS
A. Effect of Food on Drug Absorption
i. Decreased Absorption: Food can hinder the absorption of certain medications, leading to reduced efficacy.
ii. Increased Absorption: In some cases, food can enhance the absorption of drugs, improving therapeutic effects.
B. Impact of Food on Drug Metabolism: The Grapefruit Juice Effect
Grapefruit juice can inhibit cytochrome P450 enzymes, affecting the metabolism of many medications, leading to increased plasma levels and potential toxicity.
C. Impact of Food on Drug Toxicity (examples)
i. Theophylline plus caffeine: Both substances are metabolized by the same pathway, potentially leading to increased side effects.
ii. Potassium-sparing diuretics plus salt substitutes: Increased potassium levels can occur, which may result in toxicity.
iii. Aluminum-containing antacids plus citrus beverages: This combination may lead to increased absorption of aluminum, resulting in toxicity.
D. Impact of Food on Drug Action (example)
Vitamin K rich foods & warfarin: High intake of vitamin K can reduce the effectiveness of warfarin, a blood thinner/anticoagulant, due to its role in coagulation processes.
Tyramine rich food & monoamine oxidase inhibitors (MAOIs): Consuming foods high in tyramine, such as aged cheeses and cured meats, can lead to hypertensive crises when taken with MAOIs, as tyramine stimulates the release of norepinephrine.
Potassium rich foods & certain diuretics: High intake of potassium-rich foods, such as bananas and spinach, can lead to hyperkalemia in patients taking potassium-sparing diuretics, which can increase the risk of cardiac complications.
E. Timing of Drug Administration with Respect to Meals
i. On an empty stomach: Certain drugs should be taken without food to enhance absorption.
ii. With meals: Other medications might require food to mitigate side effects or enhance effects.
iii. Considerations: Patient adherence and specific drug-food combinations must be carefully evaluated.
Ch.7 Adverse Drug Reactions (ADRs)
Definition: An adverse drug reaction is any noxious, unintended, and undesired effect that occurs at normal drug doses.
Risk Factors for Adverse Drug Events
High-Risk Populations: Patients at increased risk for adverse drug events include:
The very young (children).
Older adults (geriatric patients).
The very ill.
Those taking multiple medications (polypharmacy).
Types of Drug Reactions
Iatrogenic Disease: A disease that occurs as a result of medical care or treatment, often due to unintended consequences of medication or procedures.
Idiosyncratic Effect: An adverse drug reaction that is based on an individual's genetic predisposition, resulting in unexpected responses to a drug.
Paradoxical Effect: An effect that is the opposite of the intended drug effect.
Carcinogenic Effect: A drug-induced effect leading to cancer.
Teratogenic Effect: A drug-induced defect happening during fetal development, resulting in birth defects.
Allergic Drug Reaction: The intensity of an allergic reaction is based on the degree of immune system sensitization rather than the drug dosage.
Hepatotoxicity and Liver Failure
Concerning Drug Safety: Drugs are the most common cause of acute liver failure. Hepatotoxicity is the leading reason for the removal of drugs from the market.
QT Interval Prolongation
Prolonged QT Interval Risk: Drugs that prolong the QT interval pose a substantial risk of torsades de pointes, a type of dysrhythmia that can progress to fatal ventricular fibrillation.
Drug Release and Reporting
New Drugs: At the time of a drug's release, it may be capable of causing adverse effects that have not yet been reported.
Minimizing Adverse Drug Events
Preventative Measures: To minimize adverse drug events, strategies include:
Avoiding drugs that are likely to harm a certain patient.
Monitoring patients for signs and symptoms of possible adverse effects.
Educating patients about potential adverse effects.
Monitoring organs vulnerable to specific drugs.
Regulation and Safety Information
FDA Requirements: To reduce the risk for serious reactions:
The FDA may require the manufacturer to create a Medication Guide for patients.
A boxed warning may be issued to alert prescribers of risks.
A Risk Evaluation and Mitigation Strategy (REMS) may be instituted, involving healthcare providers like patients, prescribers, and pharmacists.
Medication Errors
Significance: Medication errors are a major cause of morbidity and mortality in healthcare.
Potential Errors Originators: Medication errors can be made by:
Pharmaceutical workers.
Pharmacists.
Prescribers (doctors/nurse practitioners).
Transcriptionists.
Nurses.
Patients and their families.
Hospital Medication Order Process
Multi-Step Processing: In a hospital setting, a medication order is usually processed by several individuals, each one able to:
Introduce errors.
Identify errors made by others.
Role of Nursing in Medication Safety
Patient Safety: The nurse serves as the last line of defense against medication errors made by others, and may also be the last individual to introduce an error.
Unique Responsibility: Due to this pivotal role, nurses have a significant responsibility to ensure patient safety regarding medication administration.
Common Medication Errors
Fatal Medication Errors: The three most common types of fatal medication errors include:
Giving an overdose.
Dispensing the wrong drug.
Using the wrong route for administration.
Root Causes of Fatal Errors: The three most common causes of fatal medication errors include:
Human factors—examples include performance or knowledge deficits.
Miscommunication—such as issues resulting from illegible prescriber handwriting.
Name confusion—arising from similarities between drug names.
Cultural Shift in Error Management
Cultural Change Needed: There is a critical need for a change in institutional culture:
Move from punitive systems focusing on "naming, blaming, and shaming" to non-punitive systems.
Enable open discussions about medication errors, fostering error identification and the development of safety procedures.
Effective Measures to Reduce Medication Errors
Safety Protocols: Effective strategies to reduce medication errors include:
Utilizing a safety checklist for high-alert medications.
Transitioning from handwritten medication orders to computerized order-entry systems.
Assigning a clinical pharmacist to accompany ICU physicians on rounds.
Avoiding use of error-prone abbreviations.
Engaging and encouraging patients and their families to participate actively in the healthcare process.
Conducting medication reconciliation at every transition in care.
Implementing a computerized bar-code system that:
Identifies the administering nurse.
Ensures the drug is intended for the right patient and assesses the likelihood of adverse interactions.
Medication Reconciliation Process
Definition: Medication reconciliation is a recognized method for reducing medication errors occurring at care transition points. It consists of five steps:
Create a complete list of all current medications.
Create a list of all medications to be prescribed in the new care setting.
Compare medications on both lists.
Alert the prescriber regarding any necessary adjustments based on medication comparison.
When the patient undergoes the next transition in care, provide the updated, reconciled list to both the patient and the new provider.
Disulfiram reaction – No alcohol!
Ch. 8 : Individual Variation in Drug Responses
I. BODY WEIGHT AND COMPOSITION (body size)
Potential differences: Variations in body weight and composition can lead to different pharmacokinetics and pharmacodynamics of drugs across individuals.
Body weight versus body surface area (BSA):
- Body Weight: Total mass of an individual. Often considered in drug dosing but can overlook the relative distribution of drugs in different body compartments.
- Body Surface Area (BSA): A more precise measure that accounts for the proportionality of body size.
- BSA is calculated using the formula:
II. AGE
Infants:
- Unique pharmacokinetic characteristics (e.g., immature liver and kidney function) leading to altered drug metabolism and clearance. - Specific considerations for dosing as organ function matures.Older adults:
- Age-related physiological changes that can affect drug absorption, distribution, metabolism, and excretion (ADME). - Increased likelihood of comorbidities and polypharmacy leading to increased risk of adverse drug reactions.
III. PATHOPHYSIOLOGY
A. Kidney Disease
- Effects: Reduced renal clearance can lead to drug accumulation and toxicity. - Drug example affected by kidney disease:
- Digoxin: Requires careful monitoring in patients with renal impairment due to altered clearance.B. Liver Disease
- Effects: Hepatic function is crucial for drug metabolism; liver diseases can significantly impair drug clearance and increase the risk of adverse effects. - Drug example affected by liver disease: - Acetaminophen: Risk of hepatotoxicity due to impaired metabolism in liver dysfunction.C. Electrolyte Levels - Effects: Electrolyte imbalances (e.g., hyperkalemia) can affect drug efficacy and toxicity, particularly for drugs that alter electrolyte levels. - Drug example:
- ACE inhibitors: Can lead to further hyperkalemia and require monitoring of potassium levels.
IV. TOLERANCE
A. Pharmacodynamic Tolerance
- Definition: A decrease in drug effect resulting from adaptation of physiological systems to the drug's continued presence. - Drug example:
- Opioids: Patients may require higher doses over time due to tolerance development. - Effect on MEC (Minimum Effective Concentration):
- The need to increase drug dosage elevates the MEC, necessitating careful monitoring.B. Metabolic Tolerance
- Definition: Increased metabolism of a drug due to enzymatic induction in the liver after prolonged exposure. - Drug example:
- Barbiturates: Enhanced breakdown over time leading to reduced therapeutic effects. - Effect on MEC:
- Shifts the dosing requirements and can lead to subtherapeutic effects.C. Tachyphylaxis
- Definition: Rapid development of tolerance often occurring after just a few doses of a drug. - Drug example:
- Nitroglycerin: Tolerance can develop quickly, necessitating drug-free intervals.
V. PLACEBO EFFECT
Definition: The phenomenon whereby a patient experiences a perceived improvement in condition after receiving a treatment with no therapeutic value.
Example:
- Patients reporting pain relief after taking a sugar pill instead of an actual pain relief medication.Why is this important to consider during medication administration?
- Understanding the placebo effect is crucial for clinical trials and patient management, as it can impact treatment outcomes and patient expectations.
VI. GENETICS AND PHARMACOGENOMICS
The study of how genetic variation affects individual responses to drugs. This information is pivotal for personalized medicine, allowing for optimized drug therapy based on genetic profiles.
VII. GENDER AND RACE-RELATED VARIATIONS
A. Gender:
- Biological differences (e.g., hormonal influences) can lead to variations in drug metabolism and response between male and female patients.B. Race:
- Genetic factors in different populations may influence drug action and metabolism, leading to varied efficacy and safety profiles.
VIII. COMORBIDITIES AND DRUG INTERACTIONS
The presence of multiple health conditions can complicate treatment regimens, leading to potential adverse interactions among medications prescribed for the various conditions.
IX. DIET
Dietary factors can influence drug metabolism (e.g., grapefruit juice affecting cytochrome P450 enzyme activity) and absorption, necessitating dietary considerations when prescribing medications.
X. MEDICATION ADHERENCE
The degree to which patients correctly follow medical advice regarding their medications. Factors impacting adherence include understanding, access, and side effects of medications.
Emphasizing adherence is critical for achieving therapeutic outcomes and managing chronic conditions effectively.
Chapter 86: Complementary and Alternative Therapy
Dietary Supplement Health and Education Act of 1994
In 1994, after intensive lobbying efforts from the multibillion-dollar dietary supplement industry aimed at minimizing FDA oversight, Congress passed the Dietary Supplement Health and Education Act of 1994 (DSHEA). As discussed in Chapter 3, the Food, Drug, and Cosmetic Act requires that conventional drugs, both prescription and over-the-counter agents, undergo rigorous evaluation of safety and efficacy before receiving FDA approval for marketing. The DSHEA categorizes botanical products (herbal supplements), vitamins, and minerals as dietary (food) supplements rather than as drugs. By classifying products as dietary supplements, the DSHEA exempts them from undergoing FDA scrutiny and approval before marketing. In fact, dietary supplements can be manufactured and marketed without giving the FDA any proof that they are safe or effective. All the manufacturer must do is notify the FDA of efficacy claims. If a product eventually proves harmful or the manufacturer makes false claims, the FDA does have the authority to intervene but only after the product had been released for marketing. Furthermore, to challenge a claim of efficacy, the FDA must file suit in court; the challenge cannot be made through a simple administrative procedure.
Supplements to know for the final exam: Know what each of these can be used for and which ones increase risk for bleeding. (Will most likely be a matching question and/or SATA) (** means it increases bleeding risk)
Black cohosh x
Used for treating symptoms of menopause, including hot flashes, vaginal dryness, palpitations, depression, irritability, and sleep disturbance.
Butterbur
Used for migraine headaches, allergies, and asthma.
Anti-inflammatory, antispasmodic, and vasodilatory effects
Feverfew**
suppresses the release of arachidonic acid in platelets, which can decrease platelet aggregation and increase the risk of bleeding. (discontinue 2 weeks before surgery.)
Used for prophylaxis of migraine, allergies, asthma, RA, and psoriasis immune type disorders
Ginkgo biloba **
may suppress coagulation. Used w/caution if taking antiplatelet drugs or anticoagulants.
Used to improve memory, slow the progression of dementia, and to decrease intermittent claudication.
Echinacea
Used to simulate immune function, suppress inflammation, and treat viral infections.
St. John’s wort
Used for mild to moderate depression.
Garlic**
Cardiovascular system effects. Used to reduce levels of triglycerides and LDL cholesterol and to raise levels of HDL cholesterol.
Also, to reduce BP, suppress platelet aggregation, increase arterial elasticity, and decrease the formation of atherosclerotic plaque
Cranberry Juice**may increase the risk of bleeding if taking warfarin
Used to prevent UTIs and to decrease urine odor in patients with urinary incontinence.
Prevents bacteria from adhering to the urinary tract wall.
Ginger Root**
inhibits the production of thromboxane by platelets which suppress platelet aggregation. Increase risk for bleeding in pts taking antiplatelet drugs (aspirin) or anticoagulants (warfarin, heparin).
Used to treat vertigo and to suppress nausea and vomiting.
Inflammatory and analgesic properties – may be helpful with arthritis.
Green Tea
Used to lose weight, improve mental clarity, and prevent and treat cancers of the stomach, skin, bladder, and breast.
Saw Palmetto
Used to relieve urinary symptoms associated with benign prostatic hyperplasia (BPH)
Specific Key Points to know:
Dietary supplements are regulated under the DSHEA or 1994 and the CGMPs ruling issued in 2007.
Unlike conventional drugs, dietary supplements can be marketed without any proof of safety or efficacy.
Under the DSHEA, dietary supplements are presumed safe until proved harmful. Hence, manufacturers do not need to prove their products are safe. Rather, the FDA needs to prove they are not safe.
Dietary supplements can interact with conventional drugs, sometimes with serious results. Be sure to ask patients if they are using herbal supplements or other dietary supplements.
The word natural is not synonymous with safe. Remember, poison ivy and tobacco are natural, too.
Acetaminophen
Commonly used for pain relief and fever reduction.
Ibuprofen
Non-steroidal anti-inflammatory drug (NSAID) used for pain relief, inflammation, and fever.
Warfarin
An anticoagulant used to prevent thrombosis and embolism.
Requires monitoring of INR levels.
Patients should be aware of dietary interactions, particularly with Vitamin K-containing foods.
Nitroglycerin
A vasodilator used for angina and heart failure.
Administered sublingually for quick relief of chest pain.
Tyramine Containing Foods
Foods high in tyramine (e.g., aged cheeses, cured meats) can lead to hypertensive crises in patients taking monoamine oxidase inhibitors (MAOIs).
Vitamin K Containing Foods
High intake can reduce the effectiveness of warfarin due to its role in coagulation processes.
Foods like leafy greens (kale, spinach) should be consumed consistently.
Potassium Containing Foods
High potassium levels can pose risks for patients on certain medications such as potassium-sparing diuretics (e.g., furosemide).
Furosemide
A loop diuretic used to manage fluid retention and hypertension.
Electrolyte levels, particularly potassium, should be monitored.
Heparin
An anticoagulant used for prevention and treatment of thrombosis.
Must be monitored closely for signs of bleeding and requires dosage adjustments based on APTT.
Rights of Medication Administration and the Three Checks
Rights of Administration: Right patient, Right drug, Right dose, Right route, Right time, Right documentation.
Three Checks: 1) Check the medication against the order, 2) Check the medication before administration, 3) Check the medication after administration.
Morphine
An opioid analgesic used to manage severe pain.
Risk of respiratory depression; should be used with caution in patients with respiratory disorders.
Naloxone
An opioid antagonist used to reverse opioid overdose.
Should be readily available in settings where opioids are prescribed.
Benzodiazepines
Used for anxiety and sedation.
Side effects include sedation, dependency, and withdrawal symptoms.
Flumazenil
A benzodiazepine antagonist used to reverse the effects of benzodiazepines, particularly in overdose situations.
Ch 29: Overview and General Principles of Local Anesthetics
Definition and Function: Local anesthetics are drugs that suppress pain by blocking sodium channels and subsequently blocking impulse conduction along axons.
Site Specificity: The effects occur only in neurons located near the site of administration.
Lack of Systemic Depression: Unlike general anesthetics, local anesthetics suppress pain without causing a generalized depression of the entire nervous system.
Primary Pharmacology Components:
Basic pharmacology (classification and mechanism).
Properties of individual anesthetic agents.
Clinical application techniques.
Classification of Local Anesthetics
Chemical Categories: Local anesthetics are divided into two major groups based on their chemical structure:
Esters: For example, Cocaine, Procaine (no longer used), and Chloroprocaine.
Amides: For example, Lidocaine and Bupivacaine.
Clinical Significance of Classification: Differentiation is important because of differences in metabolism and the potential for allergic reactions (esters carry a higher risk of allergic reactions than amides).
Mechanism of Action and Selectivity
Molecular Mechanism: These agents suppress pain by physically blocking sodium channels in the axonal membrane. By preventing the influx of sodium ions, they inhibit the initiation and conduction of action potentials.
Selectivity of Effects:
Action is restricted to neurons located in the immediate vicinity of the administration site.
Ideally, the anesthetic provides localized blockade without affecting the central nervous system (CNS) unless systemic absorption occurs.
Use of Vasoconstrictors in Local Anesthesia
Common Co-administered Agent: Epinephrine is frequently used in conjunction with local anesthetics.
Benefits of Vasoconstriction:
Decreased Local Blood Flow: Restricts the movement of the anesthetic away from the site.
Delayed Systemic Absorption: Slows the rate at which the drug enter the bloodstream.
Prolonged Anesthesia: Keeps the drug at the site of action for a longer duration.
Reduced Toxicity Risk: Because systemic absorption is slower, the peak plasma levels of the anesthetic are lower, reducing the risk of systemic toxicity.
Adverse Effects of Vasoconstrictors: The absorption of the vasoconstrictor itself (e.g., Epinephrine) can lead to systemic effects:
Palpitations.
Tachycardia.
Nervousness.
Hypertension.
Management of Vasoconstrictor Toxicity: Systemic effects may be treated with alpha- and beta-adrenergic antagonists.
Adverse Effects of Local Anesthetics
Central Nervous System (CNS): Toxicity typically presents as initial excitation (e.g., tremors, seizures) followed by a period of depression (e.g., drowsiness, respiratory depression).
Cardiovascular System (CVS):
Bradycardia.
Heart block.
Reduced contractile force of the myocardium.
Hypotension.
Cardiac arrest.
Allergic Reactions: Range from mild dermatitis to anaphylaxis. These are more common with ester-type anesthetics.
Methemoglobinemia: A specific condition where hemoglobin is modified so it cannot release oxygen to tissues effectively.
Use in Labor and Delivery: Special consideration is required during use for childbirth as it can cross the placenta or impact uterine contractions.
Factors Affecting Time Course of Action
Onset of Anesthesia: The speed at which anesthesia begins depends on the ability of the anesthetic to penetrate the axon membrane, determined by Three properties:
Molecular size: Smaller molecules generally penetrate faster.
Lipid solubility: Higher solubility allows easier passage through the lipid bilayer.
Degree of ionization at tissue pH: Non-ionized forms cross membranes more easily.
Termination of Anesthesia: Primarily determined by regional blood flow. High blood flow at the site carries the anesthetic away quickly, shortening the duration of action.
Properties of Individual Local Anesthetics
Chloroprocaine:
Similar in structure to Procaine.
Carries a greater risk of allergic reactions due to its ester structure.
Available preparation is for injection only.
Lidocaine:
The most widely used local anesthetic.
Available for both topical and injectable applications.
Duration of effect is extended when administered with Epinephrine.
Also has an off-label or secondary use for treating cardiac dysrhythmias.
Cocaine:
The first local anesthetic discovered; classified as an ester-type.
Has significant effects on the sympathetic and central nervous systems.
Typically administered topically for procedures involving the ear, throat, and nose.
Onset is rapid and typically persists for approximately .
Clinical Application and Administration Guidelines
Topical Administration:
Used to numb skin or mucous membranes.
Safety Guidelines for Topical Use:
Apply the smallest amount necessary to achieve the effect.
Avoid application to large surface areas to limit systemic absorption.
Avoid application to broken, irritated, or abraded skin.
Avoid strenuous exercise, wrapping the site, or heating the site, as increased skin temperature accelerates absorption.
Administration by Injection:
Carries a significant risk and requires specialized medical skills.
Severe systemic reactions can occur; therefore, resuscitation equipment must be immediately available.
An intravenous (IV) line should be established before injection to allow for rapid treatment of potential toxicity.
Specific Injection Techniques
Infiltration Anesthesia: The anesthetic is injected directly into the immediate area where surgery or manipulation will occur.
Nerve Block: The anesthetic is injected into or near the nerves supplying the surgical field, but at a site distant from the actual field.
Epidural Anesthesia:
The anesthetic is injected into the epidural space.
The drug can reach the systemic circulation in significant amounts.
Common agents used include Lidocaine and Bupivacaine.
Ch. 30 General Anesthetics
Definition: General anesthetics are drugs that produce unconsciousness and a lack of responsiveness to all painful stimuli.
Comparison to Local Anesthetics:
Local anesthetics do not reduce consciousness.
Local anesthetics blunt pain only in a limited, specific area.
Classification: General anesthetics are divided into two main groups based on their route of administration:
Inhalation anesthetics
Intravenous anesthetics
Administration and Clinical Use
Licensed Providers: General anesthetics must be administered only by licensed professionals, specifically:
Anesthesiologists (physicians).
Certified Registered Nurse Anesthetists (CRNAs).
Procedural Uses: These agents are utilized to facilitate various invasive or distressing procedures, including:
Endoscopy.
Urologic procedures.
Radiation therapy.
Electroconvulsive therapy (ECT).
Transbronchial biopsy.
Various cardiologic procedures.
Fundamental Concepts: Pain and Sensation
Analgesia: Defined specifically as the loss of sensibility to pain.
Anesthesia: Defined as the loss of pain and the loss of all other sensations.
Basic Pharmacology of Inhalation Anesthetics
Properties of an Ideal Inhalation Anesthetic:
Produces unconsciousness.
Produces analgesia.
Provides muscle relaxation.
Induces amnesia.
Brief and pleasant induction.
Brief and pleasant emergence.
Depth of anesthesia can be raised or lowered with ease.
Minimal adverse effects.
Large margin of safety.
Balanced Anesthesia:
Because no single agent fulfills all the criteria of an ideal anesthetic, clinicians use "balanced anesthesia."
Definition: A technique employed to compensate for the lack of an ideal anesthetic by using a combination of drugs.
Purpose: To ensure that induction is smooth and rapid, and that analgesia and muscle relaxation are adequate.
Common Drug Combinations in Balanced Anesthesia:
Propofol and short-acting barbiturates (for induction).
Neuromuscular blocking agents (for muscle relaxation).
Opioids and nitrous oxide (for analgesia).
Molecular Mechanism of Action
Synaptic Transmission:
Inhalation anesthetics work by enhancing transmission at inhibitory synapses.
They simultaneously depress transmission at excitatory synapses.
GABA Receptors:
Except for nitrous oxide, all agents used today enhance the activation of receptors for gamma-aminobutyric acid (GABA).
GABA is the principal inhibitory transmitter in the central nervous system (CNS).
Minimum Alveolar Concentration (MAC)
Definition: The minimum concentration of drug in the alveolar air that will produce immobility in of patients exposed to a painful stimulus.
Significance: MAC provides an index of anesthetic potency; a low MAC indicates high potency.
Pharmacokinetics: Uptake, Distribution, and Elimination
Uptake:
Occurs from the lungs.
The greater the concentration of the anesthetic in the inspired air, the more rapid the uptake into the bloodstream.
Distribution:
Anesthetics are distributed to the CNS and other tissues.
Distribution is determined largely by regional blood flow.
Elimination:
Elimination is almost entirely performed by the lungs.
The drug is exported in the expired breath.
Metabolism:
Metabolism of inhalation anesthetics by the body is minimal.
Adverse Effects of Inhalation Anesthesia
Respiratory and Cardiac Depression: Common across most agents.
Sensitization of the Heart to Catecholamines: Increases the risk of arrhythmias.
Malignant Hyperthermia: A potentially fatal reaction characterized by a rapid rise in body temperature and severe muscle contractions.
Aspiration of Gastric Contents: Due to the loss of protective airway reflexes.
Hepatotoxicity: Potential for liver damage.
Toxicity to Operating Room Personnel: Chronic exposure to waste anesthetic gases can be harmful.
Drug Interactions and Adjuncts
Influencing Factors: Analgesics, CNS depressants, and CNS stimulants can change the amount of anesthetic required.
Opioids: Allow for a reduction in the dose of the inhalation anesthetic.
CNS Depressants: Add to the depressant effects of anesthesia, requiring dosage adjustments.
Preanesthetic Medications: Given to reduce anxiety, produce perioperative amnesia, and relieve pre- and postoperative pain. Classes include:
Benzodiazepines.
Opioids.
Clonidine (an -adrenergic agonist).
Anticholinergic drugs.
Neuromuscular Blocking Agents (NMBAs)
Purpose: Surgical procedures require skeletal muscle relaxation. NMBAs reduce the amount of anesthesia needed.
Effect: They prevent the contraction of all skeletal muscles, including the diaphragm and muscles of respiration, resulting in flaccid paralysis.
Risk: While approximately patients undergo surgery each year, approximately in wakes up during the procedure because NMBAs prevent them from moving or signaling distress while potentially being under-anesthetized.
Postanesthetic Medications
Analgesics:
For mild pain: Acetaminophen-like drugs.
For severe pain: Opioids.
Antiemetics: Used to manage postoperative nausea and vomiting (PONV).
Ondansetron [Zofran].
Promethazine.
Droperidol.
Muscarinic Antagonists:
Used to treat abdominal distention and urinary retention.
Example: Bethanechol.
Individual Inhalation Anesthetics
Isoflurane [Forane]:
The prototype of volatile inhalation anesthetics.
Properties: Acts quickly; depth of anesthesia can be adjusted easily; emergence occurs about minutes after cessation.
Limitations: Weak analgesic; muscle relaxation is inadequate for surgery (often requires an NMBA like Pancuronium).
Adverse Effects: Hypotension, respiratory depression, nausea, vomiting, and decreased urinary output.
Nitrous Oxide:
Known as "laughing gas."
Characteristcs: Very low anesthetic potency (cannot produce deep anesthesia alone) but very high analgesic potency.
Usage: Never used as the primary anesthetic; combined with other inhalation agents to enhance analgesia.
Potency Comparison: nitrous oxide provides pain relief equivalent to morphine.
Side Effects: No serious side effects beyond nausea and vomiting.
Desflurane [Suprane]:
Nearly identical in structure to isoflurane.
Indications: Induction of anesthesia in adults and maintenance of anesthesia in both adults and children.
Sevoflurane [Ultane]:
Indications: Induction and maintenance in both children and adults.
Usage: Commonly used for outpatient procedures.
Side Effects: Postoperative nausea and vomiting.
Halothane: No longer available for use in the United States.
Intravenous Anesthetics
Short-Acting Barbiturates (Thiobarbiturates):
Example: Methohexital Sodium [Brevital].
Notes: Once the mainstay for induction; usage has declined due to propofol. Can cause cardiovascular/respiratory depression and apnea if administered too rapidly.
Benzodiazepines:
Diazepam [Valium]: IV induction produces unconsciousness within minute; provides very little muscle relaxation.
Midazolam [Versed]: Produces unconsciousness within seconds; carries a risk of dangerous cardiorespiratory effects.
Propofol [Diprivan]:
The most widely used anesthetic.
Timing: Unconsciousness develops within seconds and lasts to minutes.
Uses: Induction and maintenance; sedative-hypnotic for mechanical ventilation and procedures.
Adverse Effects: Profound respiratory depression, hypotension, and a risk of bacterial infection (due to lipid-based formulation).
Etomidate:
A potent hypnotic agent used for induction.
Side Effects: Repeated administration can lead to hypotension, oliguria, electrolyte disturbances, and high incidence of PONV.
Ketamine:
Produces "dissociative anesthesia" (sedation, immobility, analgesia, and amnesia).
Adverse Psychologic Reactions: Hallucinations, disturbing dreams, and delirium. Requires a soothing environment for recovery.
Uses: Anesthesia for minor procedures.
Neuroleptic-Opioid Combination: Droperidol plus fentanyl.
Ch.31: Analgesics and Opioids
Definition of Analgesics: Analgesics are drugs that relieve pain without causing the loss of consciousness.
Effectiveness: Opioids are recognized as the most effective pain relievers available to clinicians.
Scope of Study: The study of these agents includes the introduction to opioids, their basic pharmacology, clinical use, opioid antagonists, and nonopioid centrally acting analgesics.
Terminology and Definitions
Opioid: A general term defined as any drug, whether natural or synthetic, that has actions similar to those of morphine.
Opiate: A specific term that applies only to compounds present in opium (e.g., morphine, codeine).
Endogenous Opioid Peptides: The body possesses three families of naturally occurring peptides that serve as endogenous ligands for opioid receptors:
Enkephalins.
Endorphins.
Dynorphins.
Opioid Receptors and Drug Classification
Classes of Opioid Receptors: There are three main classes of receptors, though the primary focus is on Mu and Kappa.
Mu Receptors: Activation of these receptors results in analgesia, respiratory depression, euphoria, sedation, and physical dependence.
Kappa Receptors: Activation results in analgesia and sedation; additionally, kappa activation may underlie psychotomimetic effects (hallucinations or delusions) seen with certain opioids.
Functional Classification of Drugs:
Pure Opioid Agonists: Activate both mu and kappa receptors. They produce analgesia, euphoria, sedation, respiratory depression, physical dependence, and constipation. This group includes strong agonists (e.g., morphine) and moderate-to-strong agonists.
Agonist-Antagonist Opioids: These include pentazocine, nalbuphine, butorphanol, and buprenorphine. When administered alone, they produce analgesia. However, if administered to a patient already taking a pure opioid agonist, they can antagonize the analgesia caused by the pure agonist.
Pure Opioid Antagonists: Act as antagonists at both mu and kappa receptors. They do not produce analgesia or any agonist effects. Their primary use is the reversal of respiratory and central nervous system () depression caused by opioid overdose. Naloxone [Narcan] is the prototype.
Morphine: Pharmacologic Actions and Therapeutic Use
Source: Morphine is obtained from the seedpod of the poppy plant.
Overview of Actions: Morphine provides pain relief, causes drowsiness, mental clouding, reduces anxiety, and creates a sense of well-being.
Therapeutic Use (Pain Relief): Relieves pain without affecting other senses such as sight, touch, smell, or hearing. It does not cause loss of consciousness. It functions by mimicking the actions of endogenous opioid peptides, primarily at mu receptors.
Other Actions: Includes respiratory depression, constipation, urinary retention, orthostatic hypotension, emesis, miosis, cough suppression, and biliary colic.
Detailed Adverse Effects of Morphine
Respiratory Depression:
Infants and the elderly are especially sensitive.
Onset by Route: Intravenous ( minutes), intramuscular ( minutes), subcutaneous (up to minutes). Effects may persist for to hours.
Spinal Injection: Response may be delayed by several hours.
Interactions: Depression is increased with concurrent use of other depressants (e.g., alcohol, barbiturates, benzodiazepines).
Risk Factors: Can compromise patients with asthma, emphysema, kyphoscoliosis, chronic cor pulmonale, and extreme obesity.
Constipation:
Mechanism: Caused by suppressed propulsive intestinal contractions, intensified nonpropulsive contractions, increased tone of the anal sphincter, and inhibited secretion of fluids into the intestinal lumen.
Complications: Fecal impaction, bowel perforation, rectal tearing, and hemorrhoids.
Treatment: Physical activity, increased fiber and fluid intake, stimulant laxatives, stool softeners, and polyethylene glycol.
Orthostatic Hypotension:
Mechanism: Morphine blunts the baroreceptor reflex and dilates peripheral arterioles and veins.
Patient Education: Patients should be taught to recognize symptoms (lightheadedness, dizziness) and move slowly when changing positions from supine/seated to upright.
Urinary Retention and Hesitancy:
Increases tone in the bladder sphincter and the detrusor muscle, elevating bladder pressure and causing urgency.
May interfere with voiding by suppressing the awareness of bladder stimuli.
Cough Suppression:
Acts at opioid receptors in the medulla.
Can lead to the accumulation of secretions; patients should be instructed to cough actively at regular intervals.
Emesis:
Stimulates the chemoreceptor trigger zone () in the medulla.
Reaction is greatest with the initial dose and diminishes over time.
Occurs in to of ambulatory patients but is uncommon in recumbent patients.
Euphoria and Dysphoria:
Euphoria: Exaggerated well-being via mu receptor activation.
Dysphoria: Anxiety and unease; common if morphine is taken in the absence of pain.
Sedation: Drowsiness and mental clouding. Patients should avoid hazardous activities. Management includes taking smaller doses more frequently or using opioids with short half-lives.
Miosis: Pupillary constriction. Toxic doses can result in "pinpoint" pupils.
Neurotoxicity: Symptoms include delirium, agitation, myoclonus, and hyperalgesia. Risk factors include renal impairment and prolonged high-dose use. Managed by hydration and dose reduction.
Prolonged Use Effects: Hormonal changes (decreased cortisol, LH, FSH, testosterone, and estrogen; increased prolactin) and suppressed immune function.
Morphine: Pharmacokinetics and Dependency
Pharmacokinetics: Morphine is not very lipid-soluble and does not cross the blood-brain barrier easily. Only a small fraction of a dose reaches the site of analgesic action.
Tolerance:
Increased doses are needed to achieve the same response.
Tolerance develops for analgesia, euphoria, sedation, and respiratory depression.
Cross-tolerance exists between different opioid agonists.
Note: No tolerance develops to miosis or constipation.
Physical Dependence (Abstinence Syndrome):
Initial reaction ( hours after last dose): Yawning, rhinorrhea, and sweating.
Progression: Violent sneezing, weakness, nausea, vomiting, diarrhea, abdominal cramps, bone and muscle pain, muscle spasms, and kicking movements.
Duration: Lasts to days if untreated. While unpleasant, withdrawal from opioids is not lethal, unlike depressants.
Drug Interactions: Includes depressants, anticholinergic drugs, hypotensive drugs, agonist-antagonist opioids, and opioid antagonists.
Toxicity (Overdose):
Classic Triad: Coma, respiratory depression, and pinpoint pupils.
Treatment: Ventilatory support and the antagonist Naloxone [Narcan].
Other Strong Opioid Agonists
Fentanyl:
Has times the potency of morphine.
Routes: Parenteral (surgical anesthesia), Transdermal [Duragesic] (patch; heat can accelerate absorption), and Transmucosal (lozenges [Actiq], buccal tablets [Fentora], sublingual tablets, and sublingual spray [Subsys]).
Meperidine: Characterized by a short half-life and the accumulation of a toxic metabolite. It interacts adversely with several other drugs.
Methadone: Utilized for the treatment of pain and for opioid addiction programs.
Others: Hydromorphone, oxymorphone, and levorphanol follow similar basic pharmacology as morphine.
Moderate to Strong Opioid Agonists
General Characteristics: Similar to morphine (analgesia, sedation, euphoria, respiratory depression, constipation), but they produce less analgesia and respiratory depression and have a lower abuse potential.
Codeine:
of codeine converts to morphine in the liver.
Used for pain and cough suppression.
of codeine provides the same effect as of acetaminophen.
Oxycodone: Analgesic actions are equivalent to those of codeine.
Hydrocodone: The most widely prescribed drug in the United States; often combined with acetaminophen or ibuprofen.
Tapentadol: Equivalent analgesic effects to oxycodone but causes less constipation.
Agonist-Antagonist Opioids and Specific Antagonists
Agonist-Antagonist Agents: Pentazocine, nalbuphine, butorphanol, and buprenorphine. Buprenorphine is available as a -day patch (Butrans) or sublingual film (Suboxone).
Opioid Antagonists (Pure):
Naloxone [Narcan]: Competitive antagonist used for reversing opioid overdose, reversing postoperative opioid effects, and reversing neonatal respiratory depression (if opioids were given during labor).
Methylnaltrexone [Relistor], Naloxegol [Movantik], and Naldemedine [Symproic]: Selective antagonists used to treat opioid-induced constipation () in late-stage disease by blocking mu receptors specifically in the gastrointestinal tract.
Naltrexone [ReVia, Vivitrol]: Used for opioid and alcohol abuse. It prevents euphoria if an opioid is taken but does not prevent cravings. Patients must be opioid-free before starting.
Nonopioid Centrally Acting Analgesics
General Features: Relieve pain via mechanisms unrelated to opioid receptors. They do not cause respiratory depression, physical dependence, or abuse. They are not regulated under the Controlled Substances Act.
Tramadol [Ultram]:
Mechanism: A combination of opioid and nonopioid mechanisms.
Safety Warning: There is a recognized suicide risk.
Interactions: Increased risk when used with other depressants.
Clinical Use and Management Strategies
Pain Assessment: Essential for management. Based on the patient's description. Evaluate location, characteristics, duration, triggers/alleviators, and status before drug and hour after.
Dosing Schedule: As a rule, opioids should be administered on a fixed schedule rather than PRN (as needed) to maintain therapeutic levels and avoid withdrawal.
Definitions of Dependency/Addiction:
Physical Dependence: A state where an abstinence syndrome occurs if the drug is abruptly withdrawn; this is distinct from addiction.
Abuse: Drug use inconsistent with medical or social norms.
Addiction: A behavior pattern of continued use of a psychoactive substance despite physical, psychologic, or social harm.
REMS (Risk Evaluation and Mitigation Strategy): A program developed by the to reduce opioid-related injuries and deaths.
Patient-Controlled Analgesia ():
Uses devices for patient-governed dosage within regulated limits.
More effective than traditional intramuscular therapy, which is painful and can cause bruising or hematoma.
Requires extensive patient and family education
Ch. 32: Barriers to Treating Cancer Pain
Patient Concerns and Barriers:
Concern about not being a ‐good‐ patient.
Reluctance to take pain medication.
Fear of addiction or the stigma of being thought of as an addict.
Worries about unmanageable side effects.
Concern about becoming tolerant to pain medication (requiring higher doses for the same effect).
Inability to pay for treatment.
Resistance to reporting pain.
Fear of distracting healthcare providers from treating the underlying cancer.
Fear that an increase in pain signifies that the cancer is worsening.
Healthcare System Barriers:
Low priority given to cancer pain management within the system.
Inadequate reimbursement for pain management services.
Restrictive regulation of controlled substances.
Treatment is unavailable or access to specialists/medications is limited.
Healthcare Professional Barriers:
Inadequate knowledge regarding modern pain management.
Poor assessment of pain levels.
Fear of patient addiction.
Concern about the side effects of analgesia.
Concern about patient tolerance to analgesics.
Barriers specifically related to how patients are perceived and managed.
Pathophysiology of Pain
Definition of Pain:
An unpleasant sensory and emotional experience associated with actual or potential tissue damage.
Pain is inherently personal and subjective.
The most reliable method of assessing pain is to have the patient describe his or her experience.
Neurophysiologic Basis and Types of Pain:
Nociceptive Pain: Results from injury to tissues. It is categorized into two forms:
Somatic Pain: Results from injury to somatic tissues (e.g., bones, joints, muscles).
Visceral Pain: Results from injury to visceral organs (e.g., small intestine).
Neuropathic Pain: Results from injury to peripheral nerves. This type of pain generally responds poorly to opioids.
Barriers to Treating Cancer Pain
Patient Concerns and Barriers:
Concern about not being a ‐good‐ patient.
Reluctance to take pain medication.
Fear of addiction or the stigma of being thought of as an addict.
Worries about unmanageable side effects.
Concern about becoming tolerant to pain medication (requiring higher doses for the same effect).
Inability to pay for treatment.
Resistance to reporting pain.
Fear of distracting healthcare providers from treating the underlying cancer.
Fear that an increase in pain signifies that the cancer is worsening.
Healthcare System Barriers:
Low priority given to cancer pain management within the system.
Inadequate reimbursement for pain management services.
Restrictive regulation of controlled substances.
Treatment is unavailable or access to specialists/medications is limited.
Healthcare Professional Barriers:
Inadequate knowledge regarding modern pain management.
Poor assessment of pain levels.
Fear of patient addiction.
Concern about the side effects of analgesia.
Concern about patient tolerance to analgesics.
Barriers specifically related to how patients are perceived and managed.
Pathophysiology of Pain
Definition of Pain:
An unpleasant sensory and emotional experience associated with actual or potential tissue damage.
Pain is inherently personal and subjective.
The most reliable method of assessing pain is to have the patient describe his or her experience.
Neurophysiologic Basis and Types of Pain:
Nociceptive Pain: Results from injury to tissues. It is categorized into two forms:
Somatic Pain: Results from injury to somatic tissues (e.g., bones, joints, muscles).
Visceral Pain: Results from injury to visceral organs (e.g., small intestine).
Neuropathic Pain: Results from injury to peripheral nerves. This type of pain generally responds poorly to opioids.
Causes of Pain in Cancer Patients
Direct Invasion: Pain resulting from the cancer invading surrounding tissues such as nerves, muscles, and visceral organs.
Metastatic Invasion: Pain occurring at distant sites due to the spread of the cancer.
Therapeutic Interventions (Treatment-Related Pain):
Chemotherapy: Can cause painful mucositis, diffuse neuropathies, and aseptic necrosis of joints.
Radiation: Can lead to osteonecrosis, chronic visceral pain, and peripheral neuropathy (often secondary to fibrosis of the nerves).
Surgery: Associated with specific syndromes such as phantom limb syndrome and postmastectomy syndrome.
Assessment and Ongoing Evaluation
Comprehensive Initial Assessment Goals: The primary objective is to characterize the pain and identify its underlying cause.
Components of Initial Assessment:
Assessment of Intensity and Character:
The patient’s self-report (the gold standard).
Onset and temporal pattern (when it starts, how long it lasts).
Location (where it hurts).
Quality (what it feels like, e.g., sharp, dull, burning).
Intensity (measured via pain intensity scales).
Modulating factors (what makes it better or worse).
Previous treatment (what has been tried and the results).
Impact (how it affects daily living and quality of life).
Physical and Neurologic Examination: To identify physical manifestations of pain or nerve damage.
Diagnostic Tests: Directed at finding the cause of pain.
Psychosocial Assessment: Directed at both the patient and the family to understand the emotional and social impact.
Ongoing Evaluation:
Reassess pain frequently.
Evaluate the effectiveness of interventions after sufficient time has elapsed.
Remain alert for the development of new types of pain.
Barriers to Effective Assessment:
Inaccurate reporting by the patient.
Underreporting of pain by the patient.
Language and cultural barriers that impede communication.
Principles and World Health Organization (WHO) Analgesic Ladder
General Principles of Drug Therapy:
Conduct a comprehensive pretreatment assessment.
Individualize the treatment plan for every patient.
Follow the WHO analgesic ladder and National Comprehensive Cancer Network guidelines.
Use oral therapy whenever possible.
Avoid intramuscular injections whenever possible.
Persistent Pain: Provide a fixed schedule of around-the-clock treatment. Provide additional rescue doses of a short-acting agent if breakthrough pain occurs.
Evaluate the patient frequently for both pain relief and drug side effects.
The WHO Analgesic Ladder:
Step : Mild to Moderate Pain
Nonopioid analgesics.
NSAIDs and acetaminophen.
Step : More Severe Pain
Add an opioid analgesic, such as oxycodone or hydrocodone.
Step : Severe Pain
Substitute a powerful opioid such as morphine or fentanyl.
Nonopioid Analgesics
Nonsteroidal Anti-inflammatory Drugs (NSAIDs):
Examples: Aspirin and ibuprofen.
Actions: Pain relief, suppression of inflammation, and reduction of fever.
Mechanism: Inhibition of cyclooxygenase () enzymes ( and ).
Most NSAIDs inhibit both.
Selective inhibitors (e.g., celecoxib) exist but carry a greater risk of thrombotic events.
Adverse Effects: Gastric ulceration, acute renal failure, and bleeding.
Thrombotic Risk: All NSAIDs except aspirin increase the risk of thrombotic events (e.g., myocardial infarction, stroke).
Platelet Effects: Can cause thrombocytopenia.
Dependence: They do not cause tolerance, physical dependence, or psychologic dependence.
Acetaminophen:
Example: Tylenol.
Mechanism: Inhibits in the central nervous system () but not in the periphery.
Benefits: Combining acetaminophen with an opioid can produce greater analgesia than either drug alone. It does not inhibit platelet aggregation, and does not promote gastric ulceration, renal failure, or thrombotic events.
Limitations: Lacks anti-inflammatory actions.
Drug Interactions:
Alcohol: Can lead to potentially fatal liver damage.
Warfarin: Can increase the risk of bleeding.
Opioid Analgesics
Drug Selection:
Pure opioid agonists are preferred for all cancer patients.
Opioid Rotation: Switching from one opioid to another to improve pain control or reduce side effects.
Dosage: Must be individualized for each patient.
Use with Caution: Methadone (Dolophine) and codeine.
Avoid: Meperidine (Demerol).
Routes of Administration:
Oral (preferred).
Rectal.
Transdermal.
Intravenous () and Subcutaneous.
Intramuscular (avoid when possible).
Intraspinal.
Intraventricular.
Patient-controlled analgesia ().
Managing Breakthrough Pain:
Patients may experience transient episodes of moderate to severe pain despite around-the-clock medication.
Rescue Medication: Use a strong opioid with rapid onset and short duration.
Examples: Immediate-release oral morphine, transmucosal fentanyl (Actiq, Fentora, Subsys), or fentanyl nasal spray (Lazanda).
Managing Opioid Side Effects
Respiratory Depression: Treated with Naloxone (Narcan).
Constipation: Managed with stool softeners (e.g., docusate), stimulant laxatives (e.g., senna), osmotic laxatives (e.g., sodium phosphate), and methylnaltrexone (Relistor).
Sedation: Managed with central nervous system stimulants (e.g., caffeine, methylphenidate, dextroamphetamine, modafinil).
Nausea and Vomiting: Treated with antiemetics (e.g., prochlorperazine, metoclopramide) or serotonin antagonists (e.g., granisetron, ondansetron).
Other Side Effects:
Itching (Pruritus): Treated with antihistamines (e.g., diphenhydramine).
Urinary retention.
Orthostatic hypotension.
Neurotoxicity.
Adjuvant Analgesics
Purpose: Used to complement opioids, not substitute them. They enhance analgesia, help manage concurrent symptoms that exacerbate pain, and treat opioid-induced side effects.
Classes and Examples:
Tricyclic Antidepressants: Amitriptyline (Elavil). Also bupropion, duloxetine, and venlafaxine.
Antiseizure Drugs: Gabapentin (Neurontin), pregabalin (Lyrica). Carbamazepine (Tegretol) should be used with caution.
Local Anesthetics/Antidysrhythmics: Lidocaine.
CNS Stimulants: Dextroamphetamine (Dexedrine) and methylphenidate (Ritalin).
Glucocorticoids.
Bisphosphonates: Zoledronic acid and pamidronate (used for bone pain).
Physical, Psychosocial, and Invasive Interventions
Invasive Procedures:
Neurolytic nerve block.
Radiation therapy.
Physical Interventions:
Heat and Cold applications.
Massage and Exercise.
Acupuncture.
Transcutaneous Electrical Nerve Stimulation ().
Psychosocial Interventions:
Relaxation and imagery.
Cognitive distraction.
Peer support groups.
Pain Management in Special Populations
Older Adults:
Exhibit heightened drug sensitivity.
Frequently experience undertreatment of pain.
Misconceptions to Avoid: The belief that elderly patients are insensitive to pain, can tolerate pain well, or are excessively sensitive to opioid side effects.
Increased risk of side effects and adverse drug-drug interactions.
Young Children:
Children frequently experience more pain from the chemotherapy and interventions than from the cancer itself.
Opioid Use Disorder:
Healthcare providers must strive to relieve the pain.
Avoid giving opioids simply because the patient wants to "get high," but do not withhold necessary pain relief.
Patient Education
General Issues:
Educate on the nature and causes of pain.
Stress the importance of honest self-reporting for assessment.
Discuss the plans for both drug and nondrug therapy.
Drug Therapy Education:
Clarify concepts of tolerance.
Explain the difference between physical dependence and addiction.
Address the fear of severe side effects.
Nondrug Therapy Education:
Focus on psychosocial interventions.
Direct Invasion: Pain resulting from the cancer invading surrounding tissues such as nerves, muscles, and visceral organs.
Metastatic Invasion: Pain occurring at distant sites due to the spread of the cancer.
Therapeutic Interventions (Treatment-Related Pain):
Chemotherapy: Can cause painful mucositis, diffuse neuropathies, and aseptic necrosis of joints.
Radiation: Can lead to osteonecrosis, chronic visceral pain, and peripheral neuropathy (often secondary to fibrosis of the nerves).
Surgery: Associated with specific syndromes such as phantom limb syndrome and postmastectomy syndrome.
Assessment and Ongoing Evaluation
Comprehensive Initial Assessment Goals: The primary objective is to characterize the pain and identify its underlying cause.
Components of Initial Assessment:
Assessment of Intensity and Character:
The patient’s self-report (the gold standard).
Onset and temporal pattern (when it starts, how long it lasts).
Location (where it hurts).
Quality (what it feels like, e.g., sharp, dull, burning).
Intensity (measured via pain intensity scales).
Modulating factors (what makes it better or worse).
Previous treatment (what has been tried and the results).
Impact (how it affects daily living and quality of life).
Physical and Neurologic Examination: To identify physical manifestations of pain or nerve damage.
Diagnostic Tests: Directed at finding the cause of pain.
Psychosocial Assessment: Directed at both the patient and the family to understand the emotional and social impact.
Ongoing Evaluation:
Reassess pain frequently.
Evaluate the effectiveness of interventions after sufficient time has elapsed.
Remain alert for the development of new types of pain.
Barriers to Effective Assessment:
Inaccurate reporting by the patient.
Underreporting of pain by the patient.
Language and cultural barriers that impede communication.
Principles and World Health Organization (WHO) Analgesic Ladder
General Principles of Drug Therapy:
Conduct a comprehensive pretreatment assessment.
Individualize the treatment plan for every patient.
Follow the WHO analgesic ladder and National Comprehensive Cancer Network guidelines.
Use oral therapy whenever possible.
Avoid intramuscular injections whenever possible.
Persistent Pain: Provide a fixed schedule of around-the-clock treatment. Provide additional rescue doses of a short-acting agent if breakthrough pain occurs.
Evaluate the patient frequently for both pain relief and drug side effects.
The WHO Analgesic Ladder:
Step : Mild to Moderate Pain
Nonopioid analgesics.
NSAIDs and acetaminophen.
Step : More Severe Pain
Add an opioid analgesic, such as oxycodone or hydrocodone.
Step : Severe Pain
Substitute a powerful opioid such as morphine or fentanyl.
Nonopioid Analgesics
Nonsteroidal Anti-inflammatory Drugs (NSAIDs):
Examples: Aspirin and ibuprofen.
Actions: Pain relief, suppression of inflammation, and reduction of fever.
Mechanism: Inhibition of cyclooxygenase () enzymes ( and ).
Most NSAIDs inhibit both.
Selective inhibitors (e.g., celecoxib) exist but carry a greater risk of thrombotic events.
Adverse Effects: Gastric ulceration, acute renal failure, and bleeding.
Thrombotic Risk: All NSAIDs except aspirin increase the risk of thrombotic events (e.g., myocardial infarction, stroke).
Platelet Effects: Can cause thrombocytopenia.
Dependence: They do not cause tolerance, physical dependence, or psychologic dependence.
Acetaminophen:
Example: Tylenol.
Mechanism: Inhibits in the central nervous system () but not in the periphery.
Benefits: Combining acetaminophen with an opioid can produce greater analgesia than either drug alone. It does not inhibit platelet aggregation, and does not promote gastric ulceration, renal failure, or thrombotic events.
Limitations: Lacks anti-inflammatory actions.
Drug Interactions:
Alcohol: Can lead to potentially fatal liver damage.
Warfarin: Can increase the risk of bleeding.
Opioid Analgesics
Drug Selection:
Pure opioid agonists are preferred for all cancer patients.
Opioid Rotation: Switching from one opioid to another to improve pain control or reduce side effects.
Dosage: Must be individualized for each patient.
Use with Caution: Methadone (Dolophine) and codeine.
Avoid: Meperidine (Demerol).
Routes of Administration:
Oral (preferred).
Rectal.
Transdermal.
Intravenous () and Subcutaneous.
Intramuscular (avoid when possible).
Intraspinal.
Intraventricular.
Patient-controlled analgesia ().
Managing Breakthrough Pain:
Patients may experience transient episodes of moderate to severe pain despite around-the-clock medication.
Rescue Medication: Use a strong opioid with rapid onset and short duration.
Examples: Immediate-release oral morphine, transmucosal fentanyl (Actiq, Fentora, Subsys), or fentanyl nasal spray (Lazanda).
Managing Opioid Side Effects
Respiratory Depression: Treated with Naloxone (Narcan).
Constipation: Managed with stool softeners (e.g., docusate), stimulant laxatives (e.g., senna), osmotic laxatives (e.g., sodium phosphate), and methylnaltrexone (Relistor).
Sedation: Managed with central nervous system stimulants (e.g., caffeine, methylphenidate, dextroamphetamine, modafinil).
Nausea and Vomiting: Treated with antiemetics (e.g., prochlorperazine, metoclopramide) or serotonin antagonists (e.g., granisetron, ondansetron).
Other Side Effects:
Itching (Pruritus): Treated with antihistamines (e.g., diphenhydramine).
Urinary retention.
Orthostatic hypotension.
Neurotoxicity.
Adjuvant Analgesics
Purpose: Used to complement opioids, not substitute them. They enhance analgesia, help manage concurrent symptoms that exacerbate pain, and treat opioid-induced side effects.
Classes and Examples:
Tricyclic Antidepressants: Amitriptyline (Elavil). Also bupropion, duloxetine, and venlafaxine.
Antiseizure Drugs: Gabapentin (Neurontin), pregabalin (Lyrica). Carbamazepine (Tegretol) should be used with caution.
Local Anesthetics/Antidysrhythmics: Lidocaine.
CNS Stimulants: Dextroamphetamine (Dexedrine) and methylphenidate (Ritalin).
Glucocorticoids.
Bisphosphonates: Zoledronic acid and pamidronate (used for bone pain).
Physical, Psychosocial, and Invasive Interventions
Invasive Procedures:
Neurolytic nerve block.
Radiation therapy.
Physical Interventions:
Heat and Cold applications.
Massage and Exercise.
Acupuncture.
Transcutaneous Electrical Nerve Stimulation ().
Psychosocial Interventions:
Relaxation and imagery.
Cognitive distraction.
Peer support groups.
Pain Management in Special Populations
Older Adults:
Exhibit heightened drug sensitivity.
Frequently experience undertreatment of pain.
Misconceptions to Avoid: The belief that elderly patients are insensitive to pain, can tolerate pain well, or are excessively sensitive to opioid side effects.
Increased risk of side effects and adverse drug-drug interactions.
Young Children:
Children frequently experience more pain from the chemotherapy and interventions than from the cancer itself.
Opioid Use Disorder:
Healthcare providers must strive to relieve the pain.
Avoid giving opioids simply because the patient wants to "get high," but do not withhold necessary pain relief.
Patient Education
General Issues:
Educate on the nature and causes of pain.
Stress the importance of honest self-reporting for assessment.
Discuss the plans for both drug and nondrug therapy.
Drug Therapy Education:
Clarify concepts of tolerance.
Explain the difference between physical dependence and addiction.
Address the fear of severe side effects.
Nondrug Therapy Education:
Focus on psychosocial interventions.
Ch 33: Introduction to Headache and Clinical Classifications
General Characteristics of Headaches
Headache is a common clinical symptom.
It can be triggered by a wide variety of stimuli, including:
Stress.
Fatigue.
Acute illness.
Sensory sensitivity to alcohol.
Categorization by Severity and Treatment Approach
Mild Episodes: These are typically relieved by over-the-counter (OTC) medications such as aspirin or acetaminophen.
Severe Episodes: These include more intense conditions such as migraine and cluster headaches, which often require prescription-strength pharmacological intervention.
Etiological Classifications
Identifiable Underlying Causes: Headaches that result from specific medical conditions, such as:
Severe hypertension.
Hyperthyroidism.
Tumors.
Infection.
Disorders affecting the eye, nose, sinuses, and throat.
No Identifiable Cause: Primary headache disorders where no underlying systemic or structural cause is found, specifically:
Migraine headaches.
Cluster headaches.
Overview of Pharmacological Management Strategies
Headache drugs are utilized in two primary ways:
Aborting an Ongoing Attack: Medications administered at the onset of symptoms to stop the progression of the headache.
Preventing Attacks (Prophylaxis): Long-term medication regimens intended to reduce the frequency and severity of headache occurrences.
Migraine Headache: Clinical Profile and Pathophysiology
Clinical Characteristics
Pain is described as throbbing and of moderate to severe intensity.
Associated symptoms include nausea and vomiting.
Patients often experience photophobia (sensitivity to light) and phonophobia (sensitivity to sound).
These headaches are highly debilitating and can significantly impair daily functioning.
Epidemiology and Forms
There is a significant hormonal component involved in the incidence of migraines.
A family history of migraines is a typical find in patient assessments.
Migraine with Aura: This form is preceded by visual symptoms (the aura).
Migraine without Aura: This is the more common form of the disorder.
Pathophysiology
Migraine is considered a neurovascular disorder involving the dilation and inflammation of intracranial blood vessels.
Vasodilation: This process leads directly to the sensation of pain.
Trigeminal Vascular System: The neurons within this system are central to the transmission of migraine-related pain.
Key Chemical Mediators:
Calcitonin gene–related peptide ().
Serotonin ( []).
Trigger Factors
Emotional/Physical: Anxiety, fatigue, and stress.
Biological: Menstruation.
Dietary/Environmental: Alcohol, weather changes, and tyramine-containing foods.
Pharmacotherapy for Migraine: Abortive Treatment
General Strategy
The goal is to abort an ongoing attack through two classes of drugs:
Nonspecific Analgesics: Aspirin-like drugs and opioid analgesics.
Migraine-Specific Drugs: Serotonin receptor agonists and ergot alkaloids.
Serotonin Receptor Agonists (Triptans): Sumatriptan [Imitrex]
Mechanism of Action:
Binds to specific receptors on intracranial blood vessels, leading to vasoconstriction.
Diminishes perivascular inflammation.
Therapeutic Use: Primarily used to abort an ongoing migraine attack and relieve associated symptoms.
Pharmacokinetics: Administered via oral or intranasal routes.
Adverse Effects:
Chest Symptoms: Approximately of users experience transient "heavy arms" or "chest pressure."
Coronary Vasospasm: Can lead to rare instances of angina.
Teratogenesis: Potential risk to fetal development.
General Effects: Vertigo, malaise, fatigue, and tingling sensations.
Local Effects: A very bad taste experienced when using the intranasal form.
Drug Interactions: Must not be combined with ergot alkaloids or other triptans, as all of these promote vasoconstriction and can lead to excessive vessel narrowing.
Other Serotonin Receptor Agonists
Naratriptan [Amerge]
Rizatriptan [Maxalt]
Zolmitriptan [Zomig]
Almotriptan [Axert]
Frovatriptan [Frova]
Eletriptan [Relpax]
Ergot Alkaloids: Ergotamine
Mechanism of Action: Acts as an agonist at serotonin receptor subtypes ( and ) and suppresses the release of to block inflammation in the trigeminal vascular system.
Therapeutic Status: Considered a second-line drug for stopping ongoing attacks in patients who do not respond to triptans.
Risk Factors: High risk for physical dependence.
Toxicity (Ergotism): A serious condition caused by ergot alkaloid overdose.
Contraindications: Must be avoided in pregnancy and in patients with certain vascular conditions.
Combination Abortive Therapy
Sumatriptan combined with Naproxen is an available option for treatment.
Migraine Headache: Preventive Therapy
Beta Blockers: Often the first-line choice for prophylaxis. Examples include:
Propranolol, timolol, atenolol, metoprolol, and nadolol.
Antiepileptic Drugs:
Divalproex [Depakote ER], topiramate [Topamax], gabapentin [Neurontin], and tiagabine [Gabitril].
Tricyclic Antidepressants:
Amitriptyline [Elavil].
Hormonal and Menstrual Migraine Management:
Uses estrogen gel and patches (e.g., Climara).
Combination with triptans/analgesics: frovatriptan, naratriptan, zolmitriptan, and naproxen sodium.
Other Preventive Agents:
Botulinum toxin A.
Supplements: Riboflavin (Vitamin ) and Coenzyme .
Herbal: Butterbur.
Cluster Headaches: Characteristics and Management
Clinical Presentation
Occur in a series or "cluster" of attacks.
Each individual attack lasts between and .
Pain is severe, throbbing, and unilateral, typically localized near the eye.
Ipsilateral Symptoms (same side as pain): Lacrimation (tearing), conjunctival redness, nasal congestion, rhinorrhea, ptosis (drooping eyelid), and miosis (constricted pupil).
Temporal Pattern
Attacks occur to times every day for a period of to months.
Clusters are separated by attack-free intervals lasting months to years.
Treatment
Primary therapy is directed at prophylaxis (prevention).
Prophylactic Agents:
Glucocorticoids (prednisone and dexamethasone).
Verapamil.
Lithium.